These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16905195)

  • 1. The structural evolution of dopamine D3 receptor ligands: structure-activity relationships and selected neuropharmacological aspects.
    Boeckler F; Gmeiner P
    Pharmacol Ther; 2006 Oct; 112(1):281-333. PubMed ID: 16905195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GPCR targeted library design: novel dopamine D3 receptor ligands.
    Böcker A; Sasse BC; Nietert M; Stark H; Schneider G
    ChemMedChem; 2007 Jul; 2(7):1000-5. PubMed ID: 17477344
    [No Abstract]   [Full Text] [Related]  

  • 3. Parallel synthesis and biological screening of dopamine receptor ligands taking advantage of a click chemistry based BAL linker.
    Bettinetti L; Löber S; Hübner H; Gmeiner P
    J Comb Chem; 2005; 7(2):309-16. PubMed ID: 15762761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced apomorphine sensitivity and increased binding of dopamine D2 receptors in nucleus accumbens in prepubertal rats after neonatal blockade of the dopamine D3 receptors by (+)-S14297.
    Flores-Tochihuitl J; Vargas G; Morales-Medina JC; Rivera G; De La Cruz F; Zamudio S; Flores G
    Synapse; 2008 Jan; 62(1):40-9. PubMed ID: 17957737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Penile erection and yawning induced by dopamine D2-like receptor agonists in rats: influence of strain and contribution of dopamine D2, but not D3 and D4 receptors.
    Depoortère R; Bardin L; Rodrigues M; Abrial E; Aliaga M; Newman-Tancredi A
    Behav Pharmacol; 2009 Jul; 20(4):303-11. PubMed ID: 19584712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents.
    Newman AH; Grundt P; Nader MA
    J Med Chem; 2005 Jun; 48(11):3663-79. PubMed ID: 15916415
    [No Abstract]   [Full Text] [Related]  

  • 7. Synthesis, binding affinity and SAR of new benzolactam derivatives as dopamine D3 receptor ligands.
    Ortega R; Raviña E; Masaguer CF; Areias F; Brea J; Loza MI; López L; Selent J; Pastor M; Sanz F
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1773-8. PubMed ID: 19217777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different binding modes of structurally diverse ligands for human D3DAR.
    Ortore G; Tuccinardi T; Orlandini E; Martinelli A
    J Chem Inf Model; 2010 Dec; 50(12):2162-75. PubMed ID: 21090729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hybrid approach for the design of highly affine and selective dopamine D(3) receptor ligands using privileged scaffolds of biogenic amine GPCR ligands.
    Sasse BC; Mach UR; Leppaenen J; Calmels T; Stark H
    Bioorg Med Chem; 2007 Dec; 15(23):7258-73. PubMed ID: 17826096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aromatic ring functionalization of benzolactam derivatives: new potent dopamine D3 receptor ligands.
    Ortega R; Hübner H; Gmeiner P; Masaguer CF
    Bioorg Med Chem Lett; 2011 May; 21(9):2670-4. PubMed ID: 21273071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and SAR of highly potent and selective dopamine D3-receptor antagonists: variations on the 1H-pyrimidin-2-one theme.
    Geneste H; Amberg W; Backfisch G; Beyerbach A; Braje WM; Delzer J; Haupt A; Hutchins CW; King LL; Sauer DR; Unger L; Wernet W
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1934-7. PubMed ID: 16439127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.
    Brocco M; Dekeyne A; Papp M; Millan MJ
    Behav Pharmacol; 2006 Nov; 17(7):559-72. PubMed ID: 17021388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.
    Micheli F; Bonanomi G; Braggio S; Capelli AM; Damiani F; Di Fabio R; Donati D; Gentile G; Hamprecht D; Perini O; Petrone M; Tedesco G; Terreni S; Worby A; Heidbreder C
    Bioorg Med Chem Lett; 2008 Feb; 18(3):908-12. PubMed ID: 18178090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and SAR of highly potent and selective dopamine D(3)-receptor antagonists: 1H-pyrimidin-2-one derivatives.
    Geneste H; Backfisch G; Braje W; Delzer J; Haupt A; Hutchins CW; King LL; Kling A; Teschendorf HJ; Unger L; Wernet W
    Bioorg Med Chem Lett; 2006 Feb; 16(3):490-4. PubMed ID: 16290141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and structure-activity relationship studies of hexahydropyrazinoquinolines as a novel class of potent and selective dopamine receptor 3 (D3) ligands.
    Ji M; Chen J; Ding K; Wu X; Varady J; Levant B; Wang S
    Bioorg Med Chem Lett; 2005 Mar; 15(6):1701-5. PubMed ID: 15745825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-selectivity investigations of D2-like receptor ligands by CoMFA and CoMSIA guiding the discovery of D3 selective PET radioligands.
    Salama I; Hocke C; Utz W; Prante O; Boeckler F; Hübner H; Kuwert T; Gmeiner P
    J Med Chem; 2007 Feb; 50(3):489-500. PubMed ID: 17266201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel ergopeptides as dual ligands for adenosine and dopamine receptors.
    Vendrell M; Angulo E; Casadó V; Lluis C; Franco R; Albericio F; Royo M
    J Med Chem; 2007 Jun; 50(13):3062-9. PubMed ID: 17539620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First structure-activity relationship study on dopamine D3 receptor agents with N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamide structure.
    Leopoldo M; Lacivita E; Colabufo NA; Contino M; Berardi F; Perrone R
    J Med Chem; 2005 Dec; 48(25):7919-22. PubMed ID: 16335915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational Study and Modified Design of Selective Dopamine D3 Receptor Agonists.
    Duan X; Zhang X; Xu B; Wang F; Lei M
    Chem Biol Drug Des; 2016 Jul; 88(1):142-54. PubMed ID: 26851125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CoMFA and CoMSIA investigations of dopamine D3 receptor ligands leading to the prediction, synthesis, and evaluation of rigidized FAUC 365 analogues.
    Salama I; Schlotter K; Utz W; Hübner H; Gmeiner P; Boeckler F
    Bioorg Med Chem; 2006 Sep; 14(17):5898-912. PubMed ID: 16750374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.